Literature DB >> 14605613

Cost-effectiveness of sentinel lymph node biopsy in thin melanomas.

Doreen M Agnese1, Shahab F Abdessalam, William E Burak, Cynthia M Magro, Rodney V Pozderac, Michael J Walker.   

Abstract

BACKGROUND: Consideration of sentinel lymph node biopsy (SLNB) is recommended for thin melanomas with poor prognostic features; however, few metastases are identified. The purpose of this study was to assess the cost effectiveness of SLNB in this population.
METHODS: The prospective melanoma database was reviewed to identify patients with melanomas <1.2 mm thick who had undergone SLNB. Physician and hospital charges were collected from the appropriate billing department.
RESULTS: A total of 138 patients were identified over an 8-year period (1994-2002). Two patients with positive SLNs were identified (1.4%), one with a melanoma <1 mm thick. Patient charges for SLNB ranged from $10,096 to $15,223 US dollars, compared with $1000 to $1740 US dollars for wide excision as an outpatient. Using these charges, the cost to identify a single positive SLN would be between $696,600 and $1,051,100 US dollars. The cost for wide excision would be between $69,000 and $120,100 US dollars. Assuming that all patients with a positive SLN would die of melanoma, the cost per life saved would be $627,000 to $931,000 US dollars.
CONCLUSIONS: The cost of performing SLNB in this population is great and only a small number will have disease identified that will alter treatment. These data call into question the appropriateness of SLNB for thin melanomas.

Entities:  

Mesh:

Year:  2003        PMID: 14605613     DOI: 10.1016/s0039-6060(03)00275-7

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  18 in total

1.  Prognostic value of sentinel lymph node biopsy in 121 low-risk melanomas (tumour thickness <1.00 mm) on the basis of a long-term follow-up.

Authors:  Torsten Hinz; Hojjat Ahmadzadehfar; Anja Wierzbicki; Tobias Höller; Jörg Wenzel; Hans-Jürgen Biersack; Thomas Bieber; Monika-H Schmid-Wendtner
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-12-08       Impact factor: 9.236

Review 2.  Surgery and sentinel lymph node biopsy.

Authors:  Mark B Faries; Donald L Morton
Journal:  Semin Oncol       Date:  2007-12       Impact factor: 4.929

3.  Use and Costs of Sentinel Lymph Node Biopsy in Non-Ulcerated T1b Melanoma: Analysis of a Population-Based Registry.

Authors:  Joshua N Herb; David W Ollila; Karyn B Stitzenberg; Michael O Meyers
Journal:  Ann Surg Oncol       Date:  2021-04-26       Impact factor: 5.344

4.  Sentinel node metastasectomy in thin <or=1-mm melanoma.

Authors:  Ilkka Koskivuo; Erkki Suominen; Juha Niinikoski; Lauri Talve
Journal:  Langenbecks Arch Surg       Date:  2005-07-29       Impact factor: 3.445

Review 5.  Survival is not the only valuable end point in melanoma screening.

Authors:  Clara Curiel-Lewandrowski; Caroline C Kim; Susan M Swetter; Suephy C Chen; Allan C Halpern; John M Kirkwood; Sancy A Leachman; Ashfaq A Marghoob; Michael E Ming; James M Grichnik
Journal:  J Invest Dermatol       Date:  2012-02-16       Impact factor: 8.551

6.  Predictors of occult nodal metastasis in patients with thin melanoma.

Authors:  Mark B Faries; Leslie A Wanek; David Elashoff; Byron E Wright; Donald L Morton
Journal:  Arch Surg       Date:  2010-02

7.  What is the Cost-Effective Treatment for Melanoma Patients with a Positive Sentinel Node?

Authors:  Hayley Standage; Alyssa R Hersh; Aaron Caughey; Matthew Taylor; John Vetto; Dale Han
Journal:  Ann Surg Oncol       Date:  2020-09-19       Impact factor: 5.344

Review 8.  The role of sentinel lymph node biopsy in the management of melanoma.

Authors:  Farin Amersi; Donald L Morton
Journal:  Adv Surg       Date:  2007

9.  Melanoma: Why is sentinel lymph node biopsy 'standard of care' for melanoma?

Authors:  James C Yang; Richard M Sherry; Steven A Rosenberg
Journal:  Nat Rev Clin Oncol       Date:  2014-04-15       Impact factor: 66.675

10.  Meta-analysis of sentinel lymph node positivity in thin melanoma (<or=1 mm).

Authors:  Melanie A Warycha; Jan Zakrzewski; Quanhong Ni; Richard L Shapiro; Russell S Berman; Anna C Pavlick; David Polsky; Madhu Mazumdar; Iman Osman
Journal:  Cancer       Date:  2009-02-15       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.